MCM
VIR icon

MAI Capital Management’s Vir Biotechnology VIR Stock Holding History

MAI Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.52K Buy
+504
New +$4.02K ﹤0.01% 3569
2025
Q3 		– Sell
-124
Closed -$625 – 4137
2025
Q2 		$625 Buy
+124
New +$665 ﹤0.01% 3733

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

MAI Capital Management's VIR Position: Q1 2026 in Review

MAI Capital Management opened a new position in Vir Biotechnology (VIR) in Q1 2026: 504 shares worth $4.52K. The stake represents ﹤0.01% of the portfolio and ranks #3569 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in VIR as recently as Q2 2025.

MAI Capital Management first reported a position in VIR in Q2 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • MAI Capital Management held 504 shares of Vir Biotechnology worth $4.52K as of Q1 2026.
  • Vir Biotechnology was a new MAI Capital Management position in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3569 holding.
  • MAI Capital Management first reported a position in Vir Biotechnology in Q2 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.